Vor Bio Completes Phase 3 UPSTREAM MG Enrollment and Expands Telitacicept Into Ocular MG
BOSTON, Massachusetts — September 8, 2026 Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase...
B Cells
Advertisement
Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Lupus Foundation Awards Grants to Advance Targeted Research
New York and Massachusetts, USA, August 14, 2026 The Lupus Foundation of America has announced the recipients of its...
Advertisement
